16:15 Moderator’s Opening Remarks

Kerry Chester, PhD, Professor, Molecular Medicine, University College London Cancer InstituteKerry Chester, PhD, Professor, Molecular Medicine, University College London Cancer Institute






16:20 Bispecific, Soluble TCR as the Next Therapeutic Platform

Bahija Jallal, PhD, CEO and Director of the Board, ImmunocoreBahija Jallal, PhD, CEO and Director of the Board, Immunocore

Of the two adaptive immunity recognition motifs, only antibodies have been brought to patients. However, antibody therapeutics only recognize 10% of human proteome (surface-expressed). The other motif, T cell receptor (TCR), has potential to unlock 90% of the human proteome, but requires converting a low-affinity, specificity membrane receptor into a soluble therapeutic. IMCgp100, a soluble, TCR bispecific-targeting melanoma, is the most advanced soluble TCR therapeutic in development.

17:20 Attacking Cancer Cell Surfaceomes with Recombinant Antibodies

James A. Wells, PhD, Professor, Departments of Pharmaceutical Chemistry and Cellular & Molecular Pharmacology, University of California,
    San FranciscoJames A. Wells, PhD, Professor, Departments of Pharmaceutical Chemistry and Cellular & Molecular Pharmacology, University of California, San Francisco

The cell surface proteome (surfaceome) is the primary hub for cells to communicate with the outside world. Oncogenes are known to cause huge changes in cells and we find this translates to significant remodeling of the surfaceome. We generate recombinant antibodies to detect and then attack these cells by toxifying the antibodies or recruiting immune cells to kill. I’ll discuss the technologies for surface protein analysis, an industrialized platform for rapid antibody generation using phage display, and using these tool reagents for target validation.


Antibodies with Affinity Switches

Stefan Dübel, PhD, Professor & Chair, Technische Universität Braunschweig, Institute of Biochemistry, Biotechnology and Bioinformatics

Agonists to the TNF Superfamily: Lessons Learned for TNFR2 for Autoimmunity

Denise L. Faustman, MD, PhD, Director, Immunology, Massachusetts General Hospital; Associate Professor, Medicine, Harvard Medical School

Developability Assessment to Enable Candidate Selection of Therapeutic Proteins

Steffen Hartmann, PhD, Head, Characterization, Formulation and Bioinformatics, Novartis Pharma AG

Bispecific Antibodies: Discovery, Development, and Next Generation

Tomoyuki Igawa, PhD, CEO, Head, Research, Global Biologics Leader, Chugai Pharmabody Research Pte. Ltd.

Closing the Analytical 0.1-to-2 Micron-Size Gap: Why, When, and How?

Wim Jiskoot, PhD, Professor, BioTherapeutics, Leiden University

Development of Novel Immunocytokines for Cancer Immunotherapy

Christian Klein, PhD, Head, Oncology Programs, Head, Cancer Immunotherapy Discovery, Roche Pharmaceutical Research and Early Development (pRED), Roche Innovation Center Zurich

Hot Topics in Continuous Chromatography for Protein Purification

Massimo Morbidelli, Professor, Chimica, Materiali e Ingegneria Chimica, Giulio Natta, Politecnico di Milano

Novel Formats for Antibody-Cytokine Fusion Proteins: Impact on Performance

Dario Neri, PhD, Professor, Chemistry and Applied Biosciences, Swiss Federal Institute of Technology (ETH Zürich)

Turning Receptors Off and On with Bispecific Agents: Mechanistic Insights from Biophysics and Biochemistry

Andreas Plückthun, PhD, Professor & Director, Biochemistry, University of Zurich

Antibodies to Watch in 2020

Janice M. Reichert, PhD, Executive Director, The Antibody Society, and Editor-in-Chief, mAbs

Unique Engineering Targets for Antibody Production Cell Lines: Selection, Cloning, Glycan Modifications, and Chromatin Readers

Volker Sandig, PhD, CSO, ProBioGen AGVolker Sandig, PhD, CSO, ProBioGen AG

Explorations in Antibody Product Discovery

Janine Schuurman, PhD, Corporate Vice President Research & Innovation, Antibody Research & Technology, Genmab

Evolving Manufacturing Concepts and Approaches for Gene-Edited Off-the-Shelf Cell Therapy Product Candidates

David Sourdive, PhD, Executive Vice President, Technical Operations, Cellectis

How to Build a Diversified Portfolio of Pyrrolobenzodiazepine-Based Antibody-Drug Conjugates

Patrick van Berkel, PhD, Senior Vice President, R&D, ADC Therapeutics, Ltd.

Tag-on-Demand: Exploiting Amber Codon Suppression Technology for the Enrichment of High-Expressing Membrane Protein Cell Lines

Trevor Wilkinson, PhD, Associate Director, Antibody Discovery & Protein Engineering, AstraZeneca Biopharmaceuticals Unit

An International Collaboration: Towards the Standardisation of Gene Therapy

Yuan Zhao, PhD, Principal Scientist, Leader, Gene Therapy Section, Advanced Therapy Division, NIBSC, Medicines & Healthcare Products Regulatory Agency